湖南省药品集中招标采购模式优化研究
发布时间：2018-07-27 12:57
【摘要】：中国目前还没有实行像欧美国家一样的医药分家政策,所以制药企业之间过度激烈的竞争就使得中国的制药公司形成了数量多、规模小的特点。而医院在从这些分布零散、规模庞杂的制药企业中进行药品采购过程中又存在着流通环节多、交易成本高、人为干涉多、商业贿赂严重等诸多问题,从而使得医院的药品采购价格过高,进而导致了目前中国一个极其严重的社会问题：看病难、吃药贵。为了解决这一严重的问题,中国从2000年,开始在全国范围内开展药品集中招标采购(centralist tender for drug purchase,CTFDP)工作,其中,评标是关系着药品招标采购工作成功与否的一个最重要的环节。所以,研究更合理的评标方法对加强招标评标工作的科学化、透明化,防止招标工作中的不正之风,提高招标工作质量,具有十分重要的意义。 本论文拟采用数学建模、系统分析、专家调查等方法在介绍国内集中招投标系统流程体系的基础上,重点分析招投标系统中存在的缺陷,并分别从技术层面和政策层面对医药招投标模式提出理论上的建议,通过构建药品集中采购模式评标模型应用到药品集中采购中,对专家的主观依赖性比较大,用层次分析法进行了权重的确定,并采用基于灰色关联度分析的灰色综合评价法进行评标,以期解决集中招投标采购系统可能导致的人为参与和医药腐败等问题。
[Abstract]:China has not implemented the same policy of separation of medicines as Europe and the United States, so the excessive and fierce competition among pharmaceutical companies has made the Chinese pharmaceutical companies have the characteristics of large number and small scale. However, in the process of purchasing drugs from these scattered and complex pharmaceutical enterprises, there are many problems such as more circulation links, higher transaction costs, more artificial interference, serious commercial bribery, and so on. Therefore, the purchase price of drugs in hospitals is too high, which leads to an extremely serious social problem in China: difficult to see a doctor and expensive to take medicine. In order to solve this serious problem, China began to carry out the work of centralized bidding and purchasing (centralist tender for drug purchase CTFDP in the whole country since 2000. Among them, bid evaluation is one of the most important links related to the success of the bidding and purchasing of drugs. Therefore, it is of great significance to study more reasonable bid evaluation methods for strengthening the scientific and transparent bidding evaluation work, preventing the unhealthy trend in the bidding work and improving the quality of the bidding work. On the basis of introducing the flow system of the domestic centralized bidding system, this paper mainly analyzes the defects in the bidding system by means of mathematical modeling, system analysis, expert investigation and so on. And from the technical level and the policy level of the pharmaceutical bidding model put forward theoretical suggestions, through the construction of centralized drug procurement model evaluation model applied to centralized drug procurement, the subjective dependence on experts is relatively large. The weight is determined by analytic hierarchy process (AHP), and the grey comprehensive evaluation method based on grey relational degree analysis is used to evaluate bids in order to solve the problems of artificial participation and medical corruption caused by centralized bidding procurement system.
【学位授予单位】：中南大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：F426.72;F274
本文编号：2147906
[Abstract]:China has not implemented the same policy of separation of medicines as Europe and the United States, so the excessive and fierce competition among pharmaceutical companies has made the Chinese pharmaceutical companies have the characteristics of large number and small scale. However, in the process of purchasing drugs from these scattered and complex pharmaceutical enterprises, there are many problems such as more circulation links, higher transaction costs, more artificial interference, serious commercial bribery, and so on. Therefore, the purchase price of drugs in hospitals is too high, which leads to an extremely serious social problem in China: difficult to see a doctor and expensive to take medicine. In order to solve this serious problem, China began to carry out the work of centralized bidding and purchasing (centralist tender for drug purchase CTFDP in the whole country since 2000. Among them, bid evaluation is one of the most important links related to the success of the bidding and purchasing of drugs. Therefore, it is of great significance to study more reasonable bid evaluation methods for strengthening the scientific and transparent bidding evaluation work, preventing the unhealthy trend in the bidding work and improving the quality of the bidding work. On the basis of introducing the flow system of the domestic centralized bidding system, this paper mainly analyzes the defects in the bidding system by means of mathematical modeling, system analysis, expert investigation and so on. And from the technical level and the policy level of the pharmaceutical bidding model put forward theoretical suggestions, through the construction of centralized drug procurement model evaluation model applied to centralized drug procurement, the subjective dependence on experts is relatively large. The weight is determined by analytic hierarchy process (AHP), and the grey comprehensive evaluation method based on grey relational degree analysis is used to evaluate bids in order to solve the problems of artificial participation and medical corruption caused by centralized bidding procurement system.
【学位授予单位】：中南大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：F426.72;F274
【参考文献】
相关期刊论文 前9条
1 李为相;李帮义;刘涛;;一种多属性的多物品拍卖方法研究[J];商业研究;2008年10期
2 朱悦佳,仲健心;药品集中招标采购中回扣现象博弈分析[J];当代经济科学;2004年06期
3 周蓉;政府采购招标与拍卖的博弈论模型研究[J];复旦学报(社会科学版);2002年02期
4 赵小惠,孙林岩;供应商选择模糊决策方法[J];工业工程;2002年05期
5 敬辉蓉;李传昭;;拍卖中卡特尔的两种合谋机制研究[J];管理工程学报;2008年03期
6 任建明;;转型期我国医药腐败问题研究[J];公共管理评论;2006年01期
7 黄卓君;;电子药务是治药价虚高症的良方妙药[J];消费导刊;2008年14期
8 罗小黔;郭劲松;刘剑;蔡云;刘国强;王声越;;模糊综合评价法在机电设备评标中的应用[J];贵州水力发电;2006年05期
9 余廉;对药品集中招标采购有关问题的探讨[J];广西会计;2002年09期
，本文编号：2147906
本文链接：https://www.wllwen.com/guanlilunwen/shengchanguanlilunwen/2147906.html
